Amarin and CSL Seqirus announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand. "We are excited to announce this agreement with CSL Seqirus in Australia and New Zealand, a world-class licensing partner for pharmaceuticals," said Karim Mikhail, President & CEO, Amarin. "CSL Seqirus’ highly experienced market access and commercialization teams in Australia and New Zealand are well-positioned to support the pricing and reimbursement efforts, particularly with their strong record in successfully supporting pharmaceutical benefits listings, and eventual marketing and promotion for VAZKEPA and help us to deliver this important medicine to patients in these countries." Under the terms of the agreement, CSL Seqirus will in-license VAZKEPA from Amarin and will be responsible for market access and reimbursement efforts, distribution, and commercial promotion for VAZKEPA across Australia and New Zealand. Amarin will receive an upfront payment and be eligible for event-related milestone payments of up to approximately $8 million and additional product-related milestone payments of up to approximately $4 million. Amarin will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price paid to Amarin.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMRN:
- Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
- Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
- Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
- Amarin accuses Sarissa of making ‘misstatements’